Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross margins from 74% to 57%, a net loss of $33 million, and a subscriber base shrinking by 100,000. Management views these setbacks as a strategic tradeoff for long-term growth, but upcoming quarters will test subscriber recovery and margin improvements. Meanwhile, Eli Lilly's strong revenue growth and raised outlook contrast with Hims' struggles, showing uneven impact of the partnership on their valuations.
Hims & Hers shares are down 19.66% on Pluang, trading at USD 18.43 as of Nov 11, 2026 01:21 WIB, reflecting ongoing investor caution after recent losses. Eli Lilly's stock, meanwhile, is up 0.75% at USD 1,422.84, showing steadier performance on the platform at the same time.
Hims & Hers reported a 49% increase in Q3 revenue to $890.4 million, driven by a 321% surge in international sales, partly due to the acquisition of Eucalyptus. However, gross margins fell sharply from 73.8% to 57.2%, and the company lost 100,000 sub...
Anthropic, the AI company behind Claude, is set to begin trading next week after ending its 15-day waiting period post-S-1 filing. The company aims to raise $80B-$100B with a valuation between $1.25T and $1.75T, potentially making it the largest IPO ...
Hims & Hers Health lowered its 2026 profit forecast for the third time this year after reporting a surprise $33 million quarterly loss. Revenue grew 49% to $890.4 million, but gross margin dropped due to a shift toward lower-margin weight-loss drugs....
The Health & Wellness Power Hour program encourages participants to start their mornings with small, manageable actions that build momentum over 21 days. This approach helps individuals establish a productive morning routine by focusing on incrementa...
Hims & Hers Health has struck a deal with Eli Lilly allowing patients to buy Lilly's GLP-1 medications, including the popular Zepbound injection and Foundayo pill, directly through Hims & Hers' telehealth platform. Previously, patients had to use Lil...
